Changes

|Positive (universal)||CD34

|Positive (universal)||CD34

|-

|-

|Positive (universal)||STAT6

|Positive (universal)||STAT6 (nuclear)

|-

|-

|Negative (universal)||

|Negative (universal)||

!Notes

!Notes

|-

|-

|<span class="blue-text">EXAMPLE:</span> t(9;22)(q34;q11.2)||<span class="blue-text">EXAMPLE:</span> 3'ABL1 / 5'BCR||<span class="blue-text">EXAMPLE:</span> der(22)||<span class="blue-text">EXAMPLE:</span> 20% (COSMIC)

|inv(12)(q13q13)||3'STAT6 / 5'NAB2||NA||55-100%

<span class="blue-text">EXAMPLE:</span> 30% (add reference)

|Yes  

|<span class="blue-text">EXAMPLE:</span> Yes

|Unknown

|<span class="blue-text">EXAMPLE:</span> No

|No

|<span class="blue-text">EXAMPLE:</span> Yes

|Many different breakpoints in the exons and introns are associated with this fusion. Ex: ''NAB2''ex4-''STAT6''ex2; ''NAB2''ex6-''STAT6''ex16/17

|<span class="blue-text">EXAMPLE:</span>

The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference).

|}

|}

==Individual Region Genomic Gain / Loss / LOH==

==Individual Region Genomic Gain / Loss / LOH==

 

 

{| class="wikitable sortable"

{| class="wikitable sortable"

|-

|-

|}

|}

==Characteristic Chromosomal Patterns==

==Characteristic Chromosomal Patterns==

 

 

{| class="wikitable sortable"

{| class="wikitable sortable"

|-

|-

!Notes

!Notes

|-

|-

|<span class="blue-text">EXAMPLE:</span> ''TP53''; Variable LOF mutations

|

 

 

|<span class="blue-text">EXAMPLE:</span> TSG

|<span class="blue-text">EXAMPLE:</span> TSG

|<span class="blue-text">EXAMPLE:</span> 20% (COSMIC)

|<span class="blue-text">EXAMPLE:</span> 20% (COSMIC)

|}Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.

|}Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.

==Epigenomic Alterations==

==Epigenomic Alterations==

==Genes and Main Pathways Involved==

==Genes and Main Pathways Involved==

Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Can include references in the table. Do not delete table.'')</span>

Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Can include references in the table. Do not delete table.'')</span>

!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome

!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome

|-

|-

|<span class="blue-text">EXAMPLE:</span> ''BRAF'' and ''MAP2K1''; Activating mutations

|NAB2::STAT6; Activating mutation

|<span class="blue-text">EXAMPLE:</span> MAPK signaling

|EGR Pathway

|<span class="blue-text">EXAMPLE:</span> Increased cell growth and proliferation

|Increased activation of EGR1

|-

|-

|<span class="blue-text">EXAMPLE:</span> ''CDKN2A''; Inactivating mutations

|<span class="blue-text">EXAMPLE:</span> ''CDKN2A''; Inactivating mutations